OKLAHOMA CITY, OK--(Marketwire - January 31, 2012) - Cytovance Biologics® announced today that it is has added a 1,000L bioreactor to its current mammalian facility with appropriate downstream processing facilities. Cytovance Biologics® currently specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L (w/v) from batch, fed-batch and perfusion processes and microbial production up to the 100L scale.
The 1,000L bioreactor will complement Cytovance's existing manufacturing process trains which include 100L and 500L bioreactors, 100L wave system, 20L and 200L Sartorius subs and a 100L microbial manufacturing train. Cytovance continues to provide analytical method development and process development for phase I, II, and III clinical trial materials as well as the establishment of regulatory robustness to support validation and commercial market launch for therapeutic proteins, recombinant proteins and monoclonal antibodies.
"The decision to expand our capabilities was made with careful consideration of our clients' needs. The additional state of the art Bioreactor will allow Cytovance to provide clinical material to key clients as they move through the clinic," commented Darren Head, Cytovance President & CEO.
Cytovance Biologics, a leading Oklahoma-contact based pharmaceutical services firm, provides critical manufacturing and development services that support researchers worldwide in their efforts to bring their candidate products into clinical trials and commercialization. Cytovance's experienced team of process engineers, scientists and regulatory compliance experts work with their clients -- from start to finish and allow biotech and pharma to focus on their core competence in R&D advancement. Cytovance services include cGMP contract manufacturing of therapeutic proteins and monoclonal antibodies, recombinant proteins, DNA-based therapeutics and vaccines and aseptic filling.
Cytovance Biologics® is located in a state-of-the-art research park developed by the Presbyterian Health Foundation (PHF) of Oklahoma City.
To find out more about Cytovance visit our website at www.cytovance.com or email us at firstname.lastname@example.org.